Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Pigment Cell & Melanoma Research|February 26, 2019
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600<sup>E/K</sup> mutant advanced melanomaAlain Patrick Algazi, Julia Rotow, Christian Posch, et al.
Cancers|July 14, 2023
Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of ElectroporationLuca G Campana, Adil Daud, Francesco Lancellotti, et al.
Melanoma Research|August 22, 2022
Melanoma risk during immunomodulating treatmentYixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Expert Opinion on Biological Therapy|June 15, 2012
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanomaAdil Daud, Christopher Soon, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FECPamela Munster, Douglas Marchion, Elona Bicaku, et al.
Oncogene|October 9, 2002
Roles of activated Src and Stat3 signaling in melanoma tumor cell growthGuilian Niu, Tammy Bowman, Mei Huang, et al.
Science Immunology|October 3, 2020
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasisJames C Lee, Sadaf Mehdizadeh, Jennifer Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2017
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumoursPatrick Schöffski, Michael Gordon, David C Smith, et al.
Cancers|April 13, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive AlterationsAlexandra M Haugh, Robert C Osorio, Rony A Francois, et al.
JAMA Dermatology|July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Igor Vujic, Adil Daud, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Pigment Cell & Melanoma Research|February 26, 2019
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600<sup>E/K</sup> mutant advanced melanomaAlain Patrick Algazi, Julia Rotow, Christian Posch, et al.
Cancers|July 14, 2023
Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of ElectroporationLuca G Campana, Adil Daud, Francesco Lancellotti, et al.
Melanoma Research|August 22, 2022
Melanoma risk during immunomodulating treatmentYixuan James Zheng, Wilson Ho, Martina Sanlorenzo, et al.
Expert Opinion on Biological Therapy|June 15, 2012
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanomaAdil Daud, Christopher Soon, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FECPamela Munster, Douglas Marchion, Elona Bicaku, et al.
Oncogene|October 9, 2002
Roles of activated Src and Stat3 signaling in melanoma tumor cell growthGuilian Niu, Tammy Bowman, Mei Huang, et al.
Science Immunology|October 3, 2020
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasisJames C Lee, Sadaf Mehdizadeh, Jennifer Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|October 24, 2017
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumoursPatrick Schöffski, Michael Gordon, David C Smith, et al.
Cancers|April 13, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive AlterationsAlexandra M Haugh, Robert C Osorio, Rony A Francois, et al.
JAMA Dermatology|July 30, 2015
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Igor Vujic, Adil Daud, et al.
Pageof 11